Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

▎药明康德内容团队编辑盐野义（Shionogi）今日宣布，其与UBE共同开发的在研呼吸道合胞病毒（RSV）口服抗病毒疗法S-337395，在2期临床试验中达到主要终点。接受最高剂量S-337395治疗的受试者，其病毒载量下降近90%。该研究为一项随机、安慰剂对照、双盲的2期试验，在健康成人中进行。研究评估了S-337395口服疗法（每日一次 ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Sisunatovir hydrochloride is under clinical development by Pfizer and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase III drugs for Respiratory ...

MRNA-1230 is under clinical development by Moderna and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus ...

Emergency department visits are "high" and "very high" for flu and RSV, respectively, and "elevated" for COVID-19 across the U.S., according to the CDC. As of the week ending Jan. 4, 18.6% of ...

Af­ter see­ing its Covid-19 drug fail in a Phase 3 tri­al last year, Sh­iono­gi on Thurs­day won a $375 mil­lion award from HHS to de­vel­op … ...

In the week ending Jan. 10, flu positivity testing was up 20% in California. The report shows moderate RSV activity and low COVID-19 activity in the same period. Norovirus, which causes sudden ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...